Literature DB >> 28994187

Performance of F-18 FDG PET/CT for predicting malignant potential of gastrointestinal stromal tumors: A systematic review and meta-analysis.

Seong-Jang Kim1,2, Sang-Woo Lee3.   

Abstract

BACKGROUND AND AIM: We aimed to explore the role of the diagnostic accuracy of F-18 fluorodeoxyglucose positron emission tomography (F-18 FDG PET) or positron emission tomography/computed tomography (PET/CT) for prediction of malignant potential of gastrointestinal stromal tumor (GIST) through a systematic review and meta-analysis.
METHODS: The MEDLINE, Embase, and Cochrane Library database, from the earliest available date of indexing through May 31, 2017, were searched for studies evaluating the diagnostic performance of F-18 FDG PET or PET/CT for prediction of malignant potential of GIST. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic curves.
RESULTS: Across seven studies (188 patients), the pooled sensitivity for F-18 FDG PET or PET/CT was 0.88 (95% confidence interval [CI]: 0.80-0.94) without heterogeneity (χ2  = 6.15, P = 0.72) and a pooled specificity of 0.88 (95% CI: 0.75-0.94) with heterogeneity (χ2  = 23.2, P = 0.01). LR syntheses gave an overall LR+ of 7.2 (95% CI: 3.3-15.3) and LR- of 0.13 (95% CI: 0.07-0.24). The pooled diagnostic odds ratio was 54 (95% CI: 16-181).
CONCLUSION: F-18 FDG PET or PET/CT demonstrated good sensitivity and specificity for the prediction of malignant potential of GIST. At present, the literature regarding the use of F-18 FDG PET or PET/CT for the prediction of malignant potential of GIST remains still limited; thus, further large multicenter studies would be necessary to substantiate the diagnostic accuracy of F-18 FDG PET or PET/CT prediction of malignant potential of GIST.
© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  PET/CT; gastrointestinal stromal tumor; malignant; positron emission tomography

Mesh:

Substances:

Year:  2018        PMID: 28994187     DOI: 10.1111/jgh.14015

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

1.  Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors.

Authors:  Nandakumar Menon; Mark Mandelkern
Journal:  Dig Dis Sci       Date:  2022-07-30       Impact factor: 3.487

2.  Jejunal Gastrointestinal Stromal Tumor (GIST) as a Rare Cause of GI Bleed: A Case Report.

Authors:  Haoming Liu; Abbey Santanello; Mercy Jimenez; Narendra Kumthekar
Journal:  Cureus       Date:  2022-04-19

3.  F-18 FDG PET, CT, and MRI for detecting the malignant potential in patients with gastrointestinal stromal tumors: A protocol for a network meta-analysis of diagnostic test accuracy.

Authors:  Kongyuan Wei; Bei Pan; Huan Yang; Cuncun Lu; Long Ge; Nong Cao
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

4.  PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT.

Authors:  Peter Iversen; Allan Kjeldsen Hansen; Thorbjørn Hubeck-Graudal; Lise Medrud; Kirsten Bouchelouche
Journal:  Diagnostics (Basel)       Date:  2022-01-18

5.  Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors.

Authors:  Masaya Iwamuro; Koji Miyahara; Chihiro Sakaguchi; Ryuta Takenaka; Sayo Kobayashi; Hirokazu Mouri; Shigetomi Tanaka; Tatsuya Toyokawa; Shouichi Tanaka; Mamoru Nishimura; Kenji Yamauchi; Takehiro Tanaka; Hiroyuki Okada
Journal:  J Clin Med       Date:  2020-05-01       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.